American International Group Inc. grew its holdings in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 18.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,075 shares of the biotechnology company’s stock after buying an additional 4,637 shares during the quarter. American International Group Inc. owned 0.07% of bluebird bio worth $4,131,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC boosted its holdings in bluebird bio by 9.6% during the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock worth $705,301,000 after purchasing an additional 587,236 shares during the last quarter. Capital Research Global Investors boosted its holdings in bluebird bio by 9.9% during the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock worth $576,001,000 after purchasing an additional 493,072 shares during the last quarter. Vanguard Group Inc. boosted its holdings in bluebird bio by 10.7% during the second quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock worth $373,884,000 after purchasing an additional 343,856 shares during the last quarter. American Century Companies Inc. purchased a new position in bluebird bio during the third quarter worth about $31,170,000. Finally, Voya Investment Management LLC boosted its holdings in bluebird bio by 1,251.6% during the second quarter. Voya Investment Management LLC now owns 217,398 shares of the biotechnology company’s stock worth $22,837,000 after purchasing an additional 201,313 shares during the last quarter.

Shares of bluebird bio, Inc. (BLUE) opened at $159.40 on Thursday. bluebird bio, Inc. has a 12-month low of $60.95 and a 12-month high of $174.65.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business had revenue of $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. During the same period last year, the firm earned ($2.07) EPS. The business’s revenue for the quarter was up 397.4% on a year-over-year basis. analysts expect that bluebird bio, Inc. will post -6.68 earnings per share for the current fiscal year.

BLUE has been the topic of several analyst reports. Wedbush restated an “outperform” rating and set a $174.00 price target (up from $135.00) on shares of bluebird bio in a report on Thursday, November 2nd. Cantor Fitzgerald restated a “sell” rating and set a $39.00 price target on shares of bluebird bio in a report on Thursday, September 28th. Evercore ISI upgraded shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price target on the stock in a report on Monday, October 16th. BMO Capital Markets boosted their price target on shares of bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a report on Monday, October 30th. Finally, Goldman Sachs Group restated a “buy” rating and set a $186.00 price target on shares of bluebird bio in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $137.57.

In related news, COO Susanna Gatti High sold 1,282 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $172.15, for a total transaction of $220,696.30. Following the sale, the chief operating officer now owns 13,718 shares of the company’s stock, valued at approximately $2,361,553.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Davidson sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $131.31, for a total transaction of $525,240.00. The disclosure for this sale can be found here. In the last three months, insiders sold 110,450 shares of company stock worth $15,790,373. Insiders own 3.90% of the company’s stock.

WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/07/american-international-group-inc-has-4-13-million-stake-in-bluebird-bio-inc-blue.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.